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The two main classes of adjuvant hormonal therapy
used in the treatment of postmenopausal women
with hormone receptor–positive breast cancer are
selective estrogen receptor modulators (for ex-
ample, tamoxifen) and the aromatase inhibitors
(AIs—for example, anastrozole, letrozole,
exemestane). The “gold standard” of 5 years of ad-
juvant tamoxifen has clearly been challenged (and
some would argue surpassed) by the accumulating
evidence from the adjuvant AI trials. In addition to
a tolerable side-effect profile, the AI treatment strat-
egies (upfront, switch, or extended adjuvant) have
all demonstrated improved disease-free survival
over adjuvant tamoxifen. They also offer a reduced
incidence of thromboembolic disease and endome-
trial pathology, but come at the price of increased
musculoskeletal symptoms, osteopenia and os-
teoporosis, and an associated increased fracture
rate.
Follow-up data from the Arimidex, Tamoxifen,
Alone or in Combination (ATAC) trial were just pre-
sented at the 2007 San Antonio Breast Cancer Sym-
posium (SABCS) and have recently been published 1.
With a median follow-up of 100 months, ATAC is
the longest-running AI trial to date, and its data con-
tinue to demonstrate improved efficacy for 5 years
of upfront anastrozole over tamoxifen alone. As was
seen in the last ATAC update and in the tamoxifen
overview data, the absolute difference in time to
recurrence (TTR) continues to increase even after
hormonal treatment is stopped at 5 years—the
“carryover effect”:
• At 5 years: 2.8% TTR (anastrozole 9.7% vs.
tamoxifen 12.5%)
• At 9 years: 4.8% TTR (anastrozole 17.0% vs.
tamoxifen 21.8%)
• Recurrence rates remained lower on anastrozole
as compared with tamoxifen after treatment
completion [hazard ratio (HR): 0.75; 95% con-
fidence interval: 0.61 to 0.94; p = 0.01]
Although a nonsignificant numeric excess of
non-breast cancer deaths in patients without a breast
cancer recurrence was noted in the anastrozole
group, no difference in overall survival was ob-
served (HR: 0.97; p = 0.7).
No unexpected toxicity data were reported, and
after the intended duration of endocrine therapy had
been completed, no “carryover” with respect to in-
creased fracture incidence was seen. Patients ac-
tively receiving anastrozole over tamoxifen had a
higher annual fracture rate (2.93% vs. 1.90% re-
spectively; incidence rate ratio: 1.55; p < 0.0001),
but no difference was observed in those rates after
endocrine therapy was complete (1.56% vs. 1.51%
respectively; incidence rate ratio: 1.03; p = 0.79).
Bisphosphonate use overall—let alone prophy-
laxis—was low in the trial. The hope is that pre-
emptive measures to identify and treat osteopenia
and osteoporosis, as per emerging evidence and
evolving clinical guidelines, can further reduce this
specific risk, particularly during the active treatment
phase.
Apart from a continued reduction in endome-
trial cancer incidence with anastrozole over tamox-
ifen (0.2% vs. 0.8% respectively), no statistically
significant differences in secondary malignancy
rates were observed. Also reassuring was the lack
of observed differences in cardiovascular morbid-
ity or mortality between the two groups.
Although the adjuvant AI trials have provided
many answers thus far, many questions remain. No
single “ideal” adjuvant endocrine strategy for any
given individual—let alone a given population—
has emerged. Given differences in trial design, pa-
tient populations, medications used, follow-up to
date, and lack of a published direct AI strategy com-
parison, declaring a clear “winner” is difficult. Add-
ing to the complexity, intriguing early follow-up
data from the Adjuvant Tamoxifen Longer Against
Shorter (ATLAS) trial presented at SABCS 2007 sug-
gest that longer-term tamoxifen (10 years) may even
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challenge the original premise of “gold standard”
5 year tamoxifen therapy 2.
Although trends are suggestive, no single AI trial
or adjuvant AI hormonal treatment strategy has yet
provided convincing data demonstrating a clear,
large, improvement in overall survival beyond that
achieved with 5 years of adjuvant tamoxifen alone.
All that being said, there is hope. Patients and
their clinicians have never had more treatment op-
tions at their disposal. And although the therapeutic
differences may appear modest, the Early Breast
Cancer Trialists’ Collaborative Group (2005–2006)
overview data a and cancer mortality statistics 3,4
demonstrate that successive, modest individual im-
provements in early detection, local control, and sys-
temic therapy together lead to considerably larger,
clinically meaningful differences in efficacy and
breast cancer survival, given time.
The hope is that, one day, clinicians can offer
patients effective, targeted, minimally toxic, indi-
vidualized therapy based on an integrated under-
standing of tumoural and patient genetics,
pharmacogenetics, and resistance mechanisms,
thereby maximizing the predictive and prognostic
capabilities of the various technologies available.
Until that day materializes, however, the oncology
community can anticipate covering large distances
with cumulative small steps. As long as we keep
heading in the right direction, we are bound to reach
our destination.
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